Free Trial

Galera Therapeutics (GRTX) Competitors

Galera Therapeutics logo
$0.03 +0.00 (+5.69%)
As of 03:12 PM Eastern

GRTX vs. JBIO, SLXN, CELZ, INAB, SBFM, PPBT, APLM, PMCB, BCLI, and MYNZ

Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Jade Biosciences (JBIO), Silexion Therapeutics (SLXN), Creative Medical Technology (CELZ), IN8bio (INAB), Sunshine Biopharma (SBFM), Purple Biotech (PPBT), Apollomics (APLM), Nuvilex (PMCB), Brainstorm Cell Therapeutics (BCLI), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry.

Galera Therapeutics vs. Its Competitors

Galera Therapeutics (NASDAQ:GRTX) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Galera Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, Jade Biosciences has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

Galera Therapeutics' return on equity of 0.00% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
Jade Biosciences N/A -60.01%-54.32%

50.8% of Galera Therapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by insiders. Comparatively, 24.9% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Jade Biosciences has a consensus target price of $15.00, suggesting a potential upside of 118.02%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Jade Biosciences is more favorable than Galera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Jade Biosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Jade Biosciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M-$0.26-0.10
Jade BiosciencesN/AN/A-$69.63M-$59.65-0.12

In the previous week, Jade Biosciences had 2 more articles in the media than Galera Therapeutics. MarketBeat recorded 2 mentions for Jade Biosciences and 0 mentions for Galera Therapeutics. Jade Biosciences' average media sentiment score of 1.89 beat Galera Therapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Galera Therapeutics Neutral
Jade Biosciences Very Positive

Summary

Jade Biosciences beats Galera Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRTX vs. The Competition

MetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.96M$782.13M$5.59B$9.53B
Dividend YieldN/A4.84%4.71%4.03%
P/E Ratio-0.071.3627.9619.93
Price / SalesN/A24.78389.5465.88
Price / CashN/A19.5636.3258.75
Price / Book-0.016.688.375.77
Net Income-$59.08M-$4.52M$3.25B$259.10M
7 Day PerformanceN/A-1.96%-2.50%-3.41%
1 Month PerformanceN/A5.23%7.98%8.53%
1 Year PerformanceN/A12.18%34.65%15.75%

Galera Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRTX
Galera Therapeutics
N/A$0.03
+5.7%
N/A-81.1%$1.96MN/A-0.0730Gap Up
JBIO
Jade Biosciences
2.3868 of 5 stars
$8.80
+1.3%
$15.00
+70.5%
N/A$7.39MN/A-0.1520
SLXN
Silexion Therapeutics
N/A$0.85
+2.6%
$5.00
+491.0%
N/A$7.35MN/A0.00N/AStock Split
CELZ
Creative Medical Technology
1.3473 of 5 stars
$2.78
+1.5%
N/A-26.4%$7.19M$14K-0.735
INAB
IN8bio
3.5006 of 5 stars
$2.36
+2.6%
$180.00
+7,527.1%
-91.2%$7.12MN/A-0.1720
SBFM
Sunshine Biopharma
2.9274 of 5 stars
$1.59
+1.6%
$15.00
+846.4%
+407.1%$7.11M$34.87M-0.013
PPBT
Purple Biotech
2.2553 of 5 stars
$2.73
-1.8%
$33.00
+1,108.8%
N/A$7.07MN/A-1.0420
APLM
Apollomics
1.0327 of 5 stars
$6.38
-9.8%
N/A-70.7%$7.01M$1.49M0.0045Gap Up
PMCB
Nuvilex
2.7591 of 5 stars
$1.01
+1.5%
N/A-49.0%$6.93MN/A1.364Gap Down
BCLI
Brainstorm Cell Therapeutics
1.1424 of 5 stars
$0.70
-5.5%
N/A-85.4%$6.88MN/A-0.2140Gap Down
MYNZ
Mainz Biomed
3.0493 of 5 stars
$1.99
-6.4%
$14.00
+602.1%
-86.7%$6.74M$890K-0.0330

Related Companies and Tools


This page (NASDAQ:GRTX) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners